Barchart.com
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
16.20 x 1 16.32 x 2
Post-market by (Cboe BZX)
16.60 +1.62 (+10.81%) 04/02/25 [NASDAQ]
16.20 x 1 16.32 x 2
Post-market 16.20 -0.40 (-2.41%) 16:29 ET
News & Headlines for Wed, Apr 2nd, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference GlobeNewswire - Thu Mar 27, 7:00AM CDT

ARQT : 16.60 (+10.81%)
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting GlobeNewswire - Fri Mar 7, 7:00AM CST

ARQT : 16.60 (+10.81%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Mar 5, 3:00PM CST

ARQT : 16.60 (+10.81%)
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting GlobeNewswire - Fri Feb 28, 8:00AM CST

ARQT : 16.60 (+10.81%)
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis  GlobeNewswire - Wed Feb 26, 7:00AM CST

ARQT : 16.60 (+10.81%)
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally Stocktwits - Wed Feb 26, 1:48AM CST

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.

ARQT : 16.60 (+10.81%)
VTI : 277.95 (+0.79%)
IWM : 202.66 (+1.58%)
XBI : 80.59 (+3.11%)
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update GlobeNewswire - Tue Feb 25, 3:00PM CST

ARQT : 16.60 (+10.81%)
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology GlobeNewswire - Mon Feb 24, 7:00AM CST

ARQT : 16.60 (+10.81%)
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference GlobeNewswire - Tue Feb 18, 3:35PM CST

ARQT : 16.60 (+10.81%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Feb 5, 3:00PM CST

ARQT : 16.60 (+10.81%)

Barchart Exclusives

Could This 1 Unlikely ‘Buy’-Rated Stock Be the Top Quantum Computing Winner in 2025? Barchart - 17 minutes ago
With quantum computing making waves this year, could this unlikely ‘Buy’-rated stock be the surprise breakout star of 2025? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades
Wed, Apr 09, 2025 5:00 PM UTC
Reserve Your Spot